“This is a transformative time for our Company, as we presented the first positive data in NMIBC, which we believe provides clinical evidence of the potential of bel-sar in solid tumors beyond the eye,” said Elisabet de los Pinos, PhD, Chief Executive Officer of Aura Biosciences (AURA). “We believe that bel-sar’s innovative mechanism of action may provide the first immune-ablative treatment in bladder cancer, with the goal to potentially offer safe and durable responses with a focal approach that is easily delivered by urologists in the office.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AURA:
- Aura Biosciences price target raised to $23 from $20 at Scotiabank
- Aura Biosciences price target raised to $24 from $21 at BTIG
- Aura Biosciences price target raised to $22 from $21 at H.C. Wainwright
- Closing Bell Movers: Netflix gains 5% as Q3 earnings, Q4 guidance top estimates
- Aura Biosciences Reports Positive Phase 1 Trial Results